Metabolic Fatty Liver Disease: Current Knowledge, Therapeutic Treatments, and Future Directions provides the most updated research findings and defines the current data gaps on metabolic fatty liver disease. The book extensively covers key areas in metabolic fatty liver disease research, including epidemiology (adults and children), economic burden, patient-reported outcome burden, natural history, current treatments, current diagnostic methods, controversies (NAFLD/MAFLD), current guidelines, fatty liver disease in the presence of other liver diseases as well as guidance on future research.
This book will provide translational researchers with a current and comprehensive resource dedicated to all aspects of research in metabolic fatty liver disease, identify current gaps in research and make future research recommendations. It also offers clinicians a look at important background information in metabolic fatty liver disease and thoroughly reviews the latest research in this area to inform treatment outcomes.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Contributors - p. ix 7. Preface - p. xiii 8. Chapter 1. Global epidemiology of NAFLD - p. 1 9. Chapter 2. The epidemiology of non-alcoholic fatty liver disease in the United States - p. 11 10. Chapter 3. Economic and patient reported outcome burden of NAFLD - p. 27 11. Chapter 4. Pathogenesis of NAFLD/NASH - p. 41 12. Chapter 5. Natural history of nonalcoholic fatty liver disease - p. 61 13. Chapter 6. Clinical diagnosis and evaluation pathway - p. 77 14. Chapter 7. Nonalcoholic fatty liver disease–related extrahepatic complications, associated outcomes, and their treatment considerations - p. 101 15. Chapter 8. Metabolic comorbidities, endocrine—Diabetes, polycystic ovarian syndrome, thyroid dysfunction - p. 123 16. Chapter 9. Noninvasive, serum-based evaluation of liver fibrosis in metabolic (dysfunction)-associated fatty liver disease - p. 137 17. Chapter 10. Noninvasive evaluation of liver fibrosis in MASLD—Imaging/elastography based - p. 151 18. Chapter 11. Clinical management of MASLD and MASH—An overview - p. 167 19. Chapter 12. Nonpharmacologic and nonsurgical treatment of NAFLD/NASH, obesity, and metabolic disease - p. 183 20. Chapter 13. Pharmacologic treatment of NAFLD/NASH and their related comorbidities - p. 197 21. Chapter 14. Surgical treatment of obesity for NAFLD - p. 221 22. Chapter 15. Metabolic dysfunction-associated steatotic liver disease in children and adolescents - p. 245 23. Chapter 16. Fatty liver and viral hepatitis: Prevalence, risk factors, natural course, pathogenesis, and management - p. 261 24. Chapter 17. Lean NAFLD: Prevalence, risk factors/pathogenesis, natural history, and treatment - p. 277 25. Chapter 18. Future directions for fatty liver disease - p. 297 26. Index - p. 319
Metabolic Fatty Liver Disease: Current Knowledge, Therapeutic Treatments, and Future Directions provides the most updated research findings and defines the current data gaps on metabolic fatty liver disease. The book extensively covers key areas in metabolic fatty liver disease research, including epidemiology (adults and children), economic burden, patient-reported outcome burden, natural history, current treatments, current diagnostic methods, controversies (NAFLD/MAFLD), current guidelines, fatty liver disease in the presence of other liver diseases as well as guidance on future research.
This book will provide translational researchers with a current and comprehensive resource dedicated to all aspects of research in metabolic fatty liver disease, identify current gaps in research and make future research recommendations. It also offers clinicians a look at important background information in metabolic fatty liver disease and thoroughly reviews the latest research in this area to inform treatment outcomes.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Contributors - p. ix 7. Preface - p. xiii 8. Chapter 1. Global epidemiology of NAFLD - p. 1 9. Chapter 2. The epidemiology of non-alcoholic fatty liver disease in the United States - p. 11 10. Chapter 3. Economic and patient reported outcome burden of NAFLD - p. 27 11. Chapter 4. Pathogenesis of NAFLD/NASH - p. 41 12. Chapter 5. Natural history of nonalcoholic fatty liver disease - p. 61 13. Chapter 6. Clinical diagnosis and evaluation pathway - p. 77 14. Chapter 7. Nonalcoholic fatty liver disease–related extrahepatic complications, associated outcomes, and their treatment considerations - p. 101 15. Chapter 8. Metabolic comorbidities, endocrine—Diabetes, polycystic ovarian syndrome, thyroid dysfunction - p. 123 16. Chapter 9. Noninvasive, serum-based evaluation of liver fibrosis in metabolic (dysfunction)-associated fatty liver disease - p. 137 17. Chapter 10. Noninvasive evaluation of liver fibrosis in MASLD—Imaging/elastography based - p. 151 18. Chapter 11. Clinical management of MASLD and MASH—An overview - p. 167 19. Chapter 12. Nonpharmacologic and nonsurgical treatment of NAFLD/NASH, obesity, and metabolic disease - p. 183 20. Chapter 13. Pharmacologic treatment of NAFLD/NASH and their related comorbidities - p. 197 21. Chapter 14. Surgical treatment of obesity for NAFLD - p. 221 22. Chapter 15. Metabolic dysfunction-associated steatotic liver disease in children and adolescents - p. 245 23. Chapter 16. Fatty liver and viral hepatitis: Prevalence, risk factors, natural course, pathogenesis, and management - p. 261 24. Chapter 17. Lean NAFLD: Prevalence, risk factors/pathogenesis, natural history, and treatment - p. 277 25. Chapter 18. Future directions for fatty liver disease - p. 297 26. Index - p. 319
